相关实验视频

Updated: Jul 17, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

复发/耐药地幔细胞淋巴瘤的不断变化的治疗范式

Sumukh Arun Kumar¹, Jenny Gao², Shyam A Patel³

¹Dept. of Internal Medicine, Saint Vincent Hospital, Worcester, MA, USA.

Leukemia research

|September 6, 2023

概括

管理复发性/耐火性地幔细胞淋巴瘤 (MCL) 正在发展,新的向疗法如皮尔托布鲁替尼和仿真抗原受体-T (CAR-T) 细胞疗法提供了更好的结果.

科学领域:

血液学血液学血液学
在瘤学瘤学.
临床治疗学临床治疗学

背景情况:

膜细胞淋巴瘤 (MCL) 呈现异质的临床行为,侵略性形式的存活率较低.
复发性/耐药性 (R/R) MCL的传统化疗正在被新的向性和基于细胞的疗法所取代.
由于对头对头试验数据有限,对R/R MCL缺乏最终的管理指南使治疗决策复杂化.

研究的目的:

审查R/R MCL目前的治疗选择.
讨论最近的进展,包括皮尔托布鲁替尼和CAR-T疗法.
总结基于证据的管理建议.

主要方法:

基于证据的当前文献和临床试验数据的综述.
对MCL治疗的最新批准和市场变化的分析.
评估新兴的研究药物和治疗方法.

主要成果:

皮尔托布鲁丁尼布是一种新型布鲁顿氨酸激酶 (BTK) 抑制剂,于2023年获得批准.
化学抗原受体-T (CAR-T) 疗法显示出治愈潜力,正如ZUMA-2所证明的那样.
其他几种药物如glofitamab,epcoritamab和zilovertamab vedotin正在开发中.

结论:

对于R/R MCL的治疗环境正在迅速发展,有针对性的药物和CAR-T疗法.
对老年患者和新药耐受性的考虑至关重要.
基于证据的建议对于优化R/R MCL管理至关重要.

关键词:

这是一种BTK抑制剂.双特异性抗体双特异性抗体在CART-T中,我们可以使用CAR-T.地膜细胞淋巴瘤是什么有针对性的治疗方法.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...